로그인|회원가입|고객센터|HBR Korea
페이지 맨 위로 이동
검색버튼 메뉴버튼

Bio & Pharma / Global Health

Korea United Pharm Speeds UN Cancer Drug Supply

Dong-A Ilbo | Updated 2026.02.09
Expand international procurement via Denmark’s Missionpharma
Secure first sales for key products including Vinracine Injection
Leverage production bases in Korea and Vietnam to strengthen portfolio
Broaden business scope through global NGOs and regional partnerships
 
Korea United Pharm Inc. announced on the 9th that it is substantially increasing its supply of anticancer drugs in the public procurement market targeting the UN and international organizations. This initiative is being pursued through cooperation with Denmark-based Missionpharma.

Korea United Pharm Inc. signed a supply contract for 30 types of anticancer drugs with Missionpharma in May last year, and began actual deliveries this year. Missionpharma is a specialized company that supplies pharmaceuticals to UNICEF (United Nations Children’s Fund), PAHO (Pan American Health Organization), UNDP (United Nations Development Programme), and WHO (World Health Organization). It recorded 2024 sales of approximately DKK 730 million (about KRW 169.2 billion) and is operating four overseas subsidiaries.

Last year, Korea United Pharm Inc. achieved its first results in the international procurement market, focusing on key anticancer drugs such as Vinrasin Injection (ingredient: Vincristine, a treatment for leukemia), Velbastin Injection (ingredient: Vinblastine Sulfate, a treatment for lymphoma), Unitrexate Injection (ingredient: Methotrexate, a treatment for rheumatoid arthritis and cancer), and DTI Injection (ingredient: Dacarbazine, a treatment for melanoma).

In February this year, the company will expand the supply of additional products including Daunosin Injection (ingredient: Daunorubicin, a treatment for acute leukemia), Purinetone Tablet (ingredient: Mercaptopurine, a treatment for leukemia), and Utolal Injection (ingredient: Fluorouracil, a treatment for colorectal cancer). Through this, it has demonstrated compliance with the quality standards of international organizations and an established system for stable production and supply.

A Korea United Pharm Inc. representative stated, “We plan to diversify our procurement portfolio by focusing on high value-added anticancer drugs at our domestic production base and on essential basic medicines at our plant in Vietnam.” In the medium to long term, the company intends to expand its business scope beyond UN-affiliated agencies to include international NGOs (non-governmental organizations) and regional economic cooperation bodies, thereby pioneering new opportunities in the procurement market.

Kim Sang-jun

AI-translated with ChatGPT. Provided as is; original Korean text prevails.
Popular News

경영·경제 질문은 AI 비서에게,
무엇이든 물어보세요.

Click!